Abstract Library

#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Lamarca A, Hernando-Cubero J, Alonso Gordoa T, Cros J,

Keywords: grade 3, prognosis, treatment, alkylating agents,

#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme

Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Teulé A, Simó-Servat A, Serrano R, Venegas E,

Keywords: Lanreotide, Satisfaction, Home training,

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#2773 Impact on Outcome in Patients (pts) with Advanced Neuroendocrine Neoplasms (NENs) Included in Prospective Clinical Trials (CT)

Introduction: Access to CT offers cancer pts the opportunity to receive new treatments and better monitoring of efficacy and toxicity. The increase of systemic therapy options in advanced NENs has relegated the inclusion of pts in CT to later lines of treatment as suggested in most guidelines.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hernando J

Authors: Hernando J, Vukovic P, Garcia-Alvarez A, Díaz N, Cameselle-Garcia S,

Keywords: Clinical Trial, Neuroendocrine Neoplasms, Overall Survival,

#2749 Impact of Next-Generation Sequencing Analyses on Treatment Management of Patients with Advanced Neuroendocrine Neoplasms

Introduction: Molecular genomic analyses are widely used in oncology but experience in advanced neuroendocrine neoplasms (NENs) is still limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Garcia Alvarez A

Authors: Garcia-Alvarez A, Hernando J, Vivancos A, Landolfi S, Casteras A,

Keywords: NGS, BRAF, RET,